The purpose of this study is to look at the safety of BEVACIZUMAB BS \[Pfizer\] when it was used to colorectal cancer patients in real-world clinical setting in Japan. The study population includes individuals who have a diagnosis of colorectal cancer and have been treated with Bevacizumab-Pfizer Biosimilar or Avastin between 1 December 2019 and 30 November 2024. Data source is the Medical Data Vision (MDV) database - a hospital-based claims database in Japan.
Study Type
OBSERVATIONAL
Enrollment
1,000
As provided in real world practice
As provided in real world practice
Pfizer
Tokyo, Japan
Incidence rate of "haemorrhage"
Time frame: From index date (Day 0) up to 90 days after last prescription
Incidence rate of "hypertension, hypertensive crisis"
Time frame: From index date (Day 0) up to 90 days after last prescription
Incidence rate of "proteinuria, nephrotic syndrome"
Time frame: From index date (Day 0) up to 90 days after last prescription
Incidence rate of "bone-marrow depression"
Time frame: From index date (Day 0) up to 90 days after last prescription
Incidence rate of "arterial thromboembolism"
Time frame: From index date (Day 0) up to 90 days after last prescription
Incidence rate of "cardiac failure congestive"
Time frame: From index date (Day 0) up to 90 days after last prescription
Incidence rate of "wound healing delayed"
Time frame: From index date (Day 0) up to 90 days after last prescription
Incidence rate of "gastrointestinal perforation"
Time frame: From index date (Day 0) up to 90 days after last prescription
Incidence rate of "venous thromboembolism"
Time frame: From index date (Day 0) up to 90 days after last prescription
Incidence rate of "fistula"
Time frame: From index date (Day 0) up to 90 days after last prescription
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Incidence rate of "shock, anaphylaxis, hypersensitivity reactions, infusion reaction"
Time frame: From index date (Day 0) up to next day after last prescription
Incidence rate of "interstitial pneumonia"
Time frame: From index date (Day 0) up to 90 days after last prescription
Incidence rate of "cardiac disorders (excluding "cardiac failure congestive" and "arterial thromboembolism")"
Time frame: From index date (Day 0) up to 90 days after last prescription
Incidence rate of "infections"
Time frame: From index date (Day 0) up to 90 days after last prescription